{"id":"NCT00781391","sponsor":"Daiichi Sankyo","briefTitle":"Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation","officialTitle":"A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11","primaryCompletion":"2013-04","completion":"2013-05","firstPosted":"2008-10-29","resultsPosted":"2015-03-25","lastUpdate":"2019-03-05"},"enrollment":21105,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Stroke","Atrial Fibrillation","Embolism"],"interventions":[{"type":"DRUG","name":"warfarin tablets","otherNames":[]},{"type":"DRUG","name":"Edoxaban tablets (high dose regimen-60mg)","otherNames":[]},{"type":"DRUG","name":"Edoxaban tablets (low dose regimen-30mg)","otherNames":[]},{"type":"DRUG","name":"placebo warfarin","otherNames":[]},{"type":"DRUG","name":"placebo edoxaban","otherNames":[]}],"arms":[{"label":"Warfarin/placebo edoxaban","type":"ACTIVE_COMPARATOR"},{"label":"high dose edoxaban/placebo warfarin","type":"EXPERIMENTAL"},{"label":"low dose edoxaban/placebo warfarin","type":"EXPERIMENTAL"}],"summary":"This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in individuals with atrial fibrillation. Patients will be randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, \\& Warfarin. The expected duration of the study is 24 months.","primaryOutcome":{"measure":"Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).","timeFrame":"on-treatment period 2.5 years of median study drug exposure and 2.8 year of median follow-up","effectByArm":[{"arm":"Low Dose Edoxaban/Placebo Warfarin","deltaMin":253,"sd":null},{"arm":"High Dose Edoxaban/Placebo Warfarin","deltaMin":182,"sd":null},{"arm":"Warfarin/Placebo Edoxaban","deltaMin":232,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"<.0001"},{"comp":"OG000 vs OG002","p":".0055"}]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":1009,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","Denmark","Estonia","Finland","France","Germany","Greece","Guatemala","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Norway","Peru","Philippines","Poland","Portugal","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["39791401","38985461","38828563","37100536","36987929","34962979","33760027","33663737","33357217","33148013","31777160","31597460","30586727","30236308","29967197","29748353","28862934","28666993","28302288","28077507","27706467","27609678","27402235","27387994","27358434","27207971","26908401","25769361","25769357","25104527","24947287","24302269","24251359","22398655","20934556"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3581,"n":7012},"commonTop":["urinary tract infection","nasopharyngitis","oedema peripheral","bronchitis","dizziness"]}}